Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2020-10-07 Proxy Solicitation & In…
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
Other.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Annual and Special Meeting of Shareholders along with a Management Information Circular dated September 28, 2020, for Mira X Acquisition Corp. It includes detailed information about the meeting agenda, proxy solicitation, voting instructions, and corporate governance matters related to the meeting. The content is typical of materials sent to shareholders to inform them about the meeting and solicit their votes, which aligns with the definition of Proxy Solicitation & Information Statement (PSI). It is not the actual Annual Report, nor an earnings release or other financial report. The document is lengthy (15,000 characters) and contains detailed proxy and meeting information, not just a brief announcement or a report publication notice. Therefore, the correct classification is PSI with high confidence.
2020-10-07 English
Other.pdf
Governance Information Classification · 95% confidence The document text is a detailed set of articles of incorporation or corporate bylaws for Biovaxys Technology Corp. and Lions Bay Mining Corp. It includes sections on shares, share certificates, shareholder rights, directors, officers, indemnification, dividends, and other governance-related provisions. There is no indication of financial statements, audit reports, earnings data, or meeting results. The content focuses on the internal rules, structure, and governance practices of the company. Therefore, this document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, not just an announcement or summary, so it is not a report publication announcement or regulatory filing. Confidence is high due to the clear governance content and absence of financial or meeting result data.
2020-10-07 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of an acquisition transaction by BioVaxys Technology Corp. It details the completion of the acquisition, changes in company classification, issuance of shares, management team introductions, and name change. It also includes an Early Warning Report related to share ownership by a key executive. There are no financial statements, quarterly or annual results, audit opinions, or detailed financial data presented. The document is primarily an announcement of a corporate transaction and related management and shareholding changes. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or a report publication announcement. The best fitting category is Capital/Financing Update (CAP) because it announces a significant acquisition transaction and related share issuance, which are financing and capital structure activities.
2020-10-06 English
Other.pdf
Regulatory Filings
2020-10-05 English
Filing statement - English.pdf
Regulatory Filings
2020-10-05 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2020-09-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.